Stocks›Healthcare›BNTX

BNTX

BioNTech SE

NasdaqResearch view

$98.52−0.75%

Sep 25 close · 1D EOD · Databento

HealthcareBiological Products, (No Diagnostic Substances)

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

No earnings release for BNTX is on file with the SEC.

DateEventSourceNext close

Sep 14BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer PatientsGlobeNewswireGlobeNewswire+2.20%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Follow the news. Track the move.

BNTX story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Sep 14

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

BioNTech and OncoC4 said gotistobart nearly doubled median overall survival versus standard chemotherapy in previously treated squamous NSCLC in the first median-OS readout from a randomized Phase 3 trial. The result strengthens the drug’s clinical case, but the program remains investigational and the disclosed data come from a non-pivotal stage of the study.

Since story

-0.3%

2026-09-14 → 2026-09-25

GlobeNewswire · 13d ago

View both sides →